Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DQ15HJ
|
|||
| Drug Name |
GEN1044
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
AbbVie
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oncotrophoblast glycoprotein 5T4 (TPBG) | Target Info | . | [2] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | . | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04424641) A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of AbbVie. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.